Except we still don't own 49% of Todos and I don't see how it's within the realm of fiduciary duty for us to own 49% of todos, in the end, unless lympro itself is "proven" to be worth a boatload, which is very much yet to be established.
As for price going down with news. The spike to .97 was on 2000 shares. Fake. The drop was on equally lower volume. But factually, we've been moving higher recently, slowly but surely.
Nothing new on the legal front.
(1)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links